Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance
By P. Neuvonen, M. Niemi, J. Backman. Clinical pharmacology and therapy, 2006
840 citations recorded by the source corpus.
Subfields: Pediatrics, Perinatology and Child Health, Pharmacology, Surgery
View Paper: https://www.semanticscholar.org/paper/69d7973af26e0b83db719c1d2512a24208a04201
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
Citations in the corpus
- Impact of OATP transporters on pharmacokinetics (2009, background): “Cyclosporine has increased the plasma concentrations of atorvastatin and several other statins, probably partly due to OATP1B1 inhibition (Neuvonen et al., 2006).”
- OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies (2012, background): “Treatment with cyclosporine, an inhibitor of OATP-mediated transport, is associated with increased plasma concentrations of statins (Neuvonen et al., 2006).”
- Prodrugs: design and clinical applications (2008, background): “Lipophilic simvastatin and lovastatin are well absorbed from the gastrointestinal tract and are taken up by hepatocytes by a transport mechanis”
- Membrane transporters in drug development (2010, background): “Inhibition of OATP1B1-mediated hepatic uptake appears to contribute to the significant increase in statin (for example, rosuvastatin) concentrations in blood after cyclosporine administratio”
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “The concomitant administration of cyclosporine (a potent inhibitor of OATP1B1 and ABCG2) with statins like rosuvastatin and pitavastatin will result in higher plasma levels of statins, leading to rhabdomyolysis [177].”
- Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake (2011, background): “Inhibitors of OATP1B1, such as cyclosporine, gemfibrozil , lopinavir/ritonavir, and atazanavir/ritonavir, can substantially diminish the therapeutic index of most statins (Neuvonen et al., 2006; Neuvonen, 2010).”
- Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (2019, neutral): “The most important pharmacokinetic difference among the statins is that only lovastatin, simvastatin, and atorvastatin are cytochrome P450 3A4 (CYP3A4) substrates and consequently are vulnerable to drug interactions with CYP3A4 inhibitors, some of which are commonly used.(52) Because of D ow nladed ”